Toll-Like Receptor 2 Signaling Protects Mice from Tumor Development in a Mouse Model of Colitis-Induced Cancer (original) (raw)
Figure 1
TLR2-deficiency leads to increased development of colitis-associated colon cancer.
(A) Schematic overview of the CAC model. After initial AOM injection (12.5 mg/kg), DSS was given in the drinking water (boxed areas) followed by regular drinking water. Mice were sacrificed on days 14 or 61 post AOM injection (Day 61: n = 19 WT, n = 21 TLR2−/− mice). (B) Percent weight change during AOM-DSS treatment. (C) Mouse mortality during AOM-DSS treatments. (D) Number of colorectal tumors per mouse induced by AOM-DSS treatment at day 61. (E) Number of tumors per mouse located in proximal or distal colons in WT or TLR2−/− mice. (F) Size distribution of colorectal tumors formed in WT or TLR2−/− mice. (G) Tumor burden in AOM-DSS treated WT or TLR2−/− mice. All tests were performed using 95% confidence intervals. Data are expressed as means ± SEM. * = p<0.05, ** = p<0.01, *** = p<0.001.